NewAmsterdam Pharma (NAMS) EBITDA (2023 - 2026)

NewAmsterdam Pharma has disclosed EBITDA across 4 years of filings, most recently posting -$49.0 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$49.0 million, down 23.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$212.9 million (down 13.66% YoY), and the FY2025 annual result was -$203.5 million, up 15.76% from the prior year.
• EBITDA came in at -$49.0 million for Q1 2026 at NewAmsterdam Pharma, up from -$74.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$16.6 million in Q3 2024 to a low of -$93.8 million in Q1 2024.
• The 4-year median for EBITDA is -$47.1 million (2023), against an average of -$51.6 million.
• Across the five-year window, EBITDA soared 64.68% in 2024 and slumped 330.66% in 2025, its largest moves.
• NewAmsterdam Pharma's EBITDA stood at -$49.5 million in 2023, then sank by 86.14% to -$92.1 million in 2024, then increased by 18.84% to -$74.8 million in 2025, then surged by 34.45% to -$49.0 million in 2026.
• The last three EBITDA figures came in at -$49.0 million (Q1 2026), -$74.8 million (Q4 2025), and -$71.7 million (Q3 2025), per Business Quant data.